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“The purpose of continuing medical education (CME) is to
enhance the physician’s ability to care for patients. It is the
responsibility of the accredited provider of a CME activity
to assure that the activity is designed primarily for that
purpose” (1).
Each year, all physicians participate as attendees or faculty
in a variety of CME meetings. It may be medical or cardiac
grand rounds at each institution, or it may be a one-day or
several-day course sponsored by a variety of providers,
including the American College of Cardiology (ACC).
Institutions such as the ACC must be accredited in order to
provide CME, which will count toward the requirements
for relicensing. Although CME meetings are relatively
common, it is still necessary for a physician to be sure to get
his or her required number of hours per year. Many times,
the attendee may travel to a vacation spot to combine CME
with vacation. Alternatively, one might prefer a more
intense experience all day, and sometimes into the night, to
limit the time away from the practice. It is likely that all
physicians understand that an organization like the ACC
has to be accredited in order to provide CME. This is done
by the Accreditation Council for Continuing Medical Ed-
ucation (ACCME). It is less likely that physicians under-
stand the process involved in acquiring this accreditation or
the standards for commercial support.
Because the pharmaceutical industry contributes consid-
erable funding to CME courses, it is of great interest to
review some of the standards governing that support. The
current standards have been in place since 1992 and are now
being studied with a view toward the probability that they
will be updated. I recently served on a working group of the
College to review the 1992 standards for commercial sup-
port and to make suggestions to the ACCME for potential
change. Some of my thoughts about these standards for
commercial support are listed below, particularly from the
perspective of someone who has directed an ACC extramu-
ral program for 25 years.
As a program director, I must be sure that the program is
free of commercial bias. When products are discussed, the
information should be objective and based on scientific
methods and trials. Generic names should be used, and
speakers should give a balanced view of therapeutic alterna-
tives. Potential conflicts of interest should be disclosed to
the audience. I believe that this is done best when speakers
show initial slides outlining their conflicts of interest (2).
The content of slides and reference materials should be the
responsibility of the speaker and should not, by either
content or format, advance proprietary interests of a given
pharmaceutical company. Neither exhibits nor sales activi-
ties should occur in the room(s) where presentations are
being made. Funds originating from a commercial source
should not be used to pay for the travel, lodging, registration
fees, honoraria, or personal expenses of non-faculty attend-
ees. Selected scholarships for students, residents, or fellows
may be appropriate. Payments of reasonable honoraria and
expenses for faculty is appropriate, but they should be made
through the CME provider and not made directly from the
company. Thus, commercial support should be in the form
of educational grants to the CME provider, such as the
ACC. I believe that all of us would agree that the above
guidelines are laudable and are intended to eliminate bias
from the faculty presentations—or at the very least to alert
the attendees to potential conflicts of interest of the speak-
ers.
There are some difficulties with the current standards,
however. When an unlabeled use of a drug is discussed, it is
the responsibility of the faculty to let the audience know
that the product is not labeled for that use. For example, if
I were to discuss the potential benefit of amiodarone in the
treatment of dilated cardiomyopathy, I would have to
explicitly indicate that this was not a labeled use. The
difficulty for speakers is that the approved uses of a drug are
always changing and it is difficult to be sure what the labeled
use might be at any given time. Furthermore, many drugs
may still be useful in circumstances where they are not
approved. I find compliance with this requirement of the
standards to be difficult, if not impossible.
There have been widely divergent views on the role of
commercial companies in providing funds for CME activ-
ities. Two recent back-to-back articles in the Journal of the
American Medical Association illustrate this point. Dr. Ar-
nold Relman flatly states, “The pharmaceutical industry has
gone too far” (3). He believes that the ACCME standards
are permissive and ambiguous. He provides arguments for
eliminating most, if not all, pharmaceutical support and
requiring physicians to pay the extra fees for CME. Al-
though this is a laudable goal, physicians are currently
complaining about the high cost of CME activities, even
with pharmaceutical support. With physicians working
harder and harder for less and less, this would be a
particularly difficult time to substantially raise fees for CME
activities. He attacks the assertion that companies are only
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after good will and not increased sales. On that point he is
probably right.
The counterpoint article (4) is by Alan F. Holmer, JD,
who is stating the viewpoint of the Pharmaceutical Research
and Manufacturers of America. He points out that the
pharmaceutical industry is proud to sponsor CME activities
and that it serves a “mutual interest to ensure that patients
receive the most up-to-date and appropriate care.” He
indicates full support for the ACCME guidelines regarding
commercial sponsorship. In a recent survey, he reports that
81% of responding physicians participate in CME to
maintain state licensure requirements and that 42% asserted
that their most important reason for attending was to keep
up to date.
My own view is probably somewhere in between these
two articles. An alliance between the pharmaceutical indus-
try and organized cardiology has been a very positive thing
in many ways, including sponsorship of fellowships, re-
search funding (American Heart Association), and support
for CME. With appropriate guidelines such as the ACCME
guidelines, I believe that physicians can receive high-quality
education with a minimum of commercial bias. Furthermore,
physicians can generally recognize such bias when they see it. It
will be interesting to see if the guidelines change substantially
during this revision. For 10 years, however, I believe that they
have served us well and will continue to do so in the future.
Send correspondence to: William W. Parmley, MD, MACC,
Editor-in-Chief, Journal of the American College of Cardiology, 415
Judah St., San Francisco, California 94122.
REFERENCES
1. Standards for Commercial Support of Continuing Medical Education.
Accreditation Council for Continuing Medical Education. Approved
March 20, 1992.
2. Parmley WW. Full disclosure: the antidote to conflict of interest.
J Am Coll Cardiol 2000;35:1693.
3. Relman AS. Separating continuing medical education from pharma-
ceutical marketing. JAMA 2001;285:2009–12.
4. Holmer AF. Industry strongly supports continuing medical education.
JAMA 2001;285:2012–4.
917JACC Vol. 38, No. 3, 2001 Parmley
September 2001:916–7 Editor’s Page
